Detalhe da pesquisa
1.
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet
; 399(10336): 1718-1729, 2022 04 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35367007
2.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Lancet Oncol
; 23(11): 1378-1388, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36265502
3.
The role of opioids in cancer response to immunotherapy.
J Transl Med
; 19(1): 119, 2021 03 23.
Artigo
Inglês
| MEDLINE | ID: mdl-33757546
4.
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
Oncologist
; 24(6): e327-e337, 2019 06.
Artigo
Inglês
| MEDLINE | ID: mdl-30796151
5.
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Cancer Immunol Immunother
; 68(1): 97-107, 2019 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-30311027
6.
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice.
J Transl Med
; 17(1): 376, 2019 11 15.
Artigo
Inglês
| MEDLINE | ID: mdl-31730009
7.
Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.
Front Immunol
; 15: 1346687, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38495872
8.
Primary Mucosal Melanoma: Clinical Experience from a Single Italian Center.
Curr Oncol
; 31(1): 588-597, 2024 Jan 22.
Artigo
Inglês
| MEDLINE | ID: mdl-38275835
9.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
J Clin Oncol
; 42(14): 1619-1624, 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38452313
10.
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin?
J Pers Med
; 13(3)2023 Feb 26.
Artigo
Inglês
| MEDLINE | ID: mdl-36983597
11.
The Impact of Drug-Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma.
Cancers (Basel)
; 15(18)2023 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37760556
12.
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Eur J Cancer
; 191: 113246, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37549531
13.
Cross-Cultural Adaptation and Preliminary Validation of Upper Limb Lymphedema Quality of Life Questionnaire (ULL-27) in Italian Female Patients with Breast Cancer-Related Lymphedema.
Lymphat Res Biol
; 20(6): 651-658, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35404129
14.
Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
Cancers (Basel)
; 14(15)2022 Jul 29.
Artigo
Inglês
| MEDLINE | ID: mdl-35954369
15.
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
J Cancer Res Clin Oncol
; 148(9): 2529-2538, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-34595541
16.
Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Sci Rep
; 12(1): 5448, 2022 03 31.
Artigo
Inglês
| MEDLINE | ID: mdl-35361879
17.
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Eur J Cancer
; 176: 207-217, 2022 11.
Artigo
Inglês
| MEDLINE | ID: mdl-36202690
18.
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Eur J Cancer
; 157: 250-258, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34536948
19.
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
Clin Colorectal Cancer
; 20(4): 318-325, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34380594
20.
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
BMC Cancer
; 10: 567, 2010 Oct 19.
Artigo
Inglês
| MEDLINE | ID: mdl-20958992